SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Goldring S, Goldring M. Clinical aspects, pathology and pathophysiology of osteoarthritis. J Musculoskelet Neuronal Interact 2006;6:3768.
  • 2
  • 3
    Hunter DJ, McDougall JJ, Keefe FJ. The symptoms of osteoarthritis and the genesis of pain. Rheum Dis Clin North Am 2008;34:62343.
  • 4
    National Collaborating Centre for Chronic Conditions.Osteoarthritis: national clinical guideline for care and management in adults.London:Royal College of Physicians;2008.
  • 5
    Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:66981.
  • 6
    Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:13762.
  • 7
    Eli Lilly Canada Inc.Product monograph Cymbalta.Toronto:Eli Lilly Canada;2011.
  • 8
  • 9
    Chappell A, Ossanna M, Liu-Seifert H, Iyengar S, Skljarevski V, Li L, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009;146:25360.
  • 10
    Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:3341.
  • 11
    Trivedi MH. The link between depression and physical symptoms. Prim Care Companion J Clin Psychiatry 2004;6:126.
  • 12
    Brunton S, Wang F, Edwards SB, Crucitti AS, Ossanna MJ, Walker DJ, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010;33:393407.
  • 13
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:11727.
  • 14
    Walley T. Pharmacoeconomics and economic evaluation of drug therapies. In: Haycox A, Boland A, editors.Pharmacoeconomics. 1st ed.London:Churchill Livingstone;2004. p.6775.
  • 15
    World Health Organization.Macroeconomics and health: investing in health for economic development. Report of the WHO Commission on Macroeconomics and Health.Geneva:World Health Organization;2001.
  • 16
    Régie de l'assurance maladie du Québec. List of medications.2011. URL: http://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_cor1_2010_06_01_en.pdf.
  • 17
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:47381.
  • 18
    Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care 2008;46:34956.
  • 19
    Canadian Agency for Drugs and Technologies in Health.Guidelines for the economic evaluation of health technologies: Canada. 3rd ed.Ottawa:Canadian Agency for Drugs and Technologies in Health;2006.
  • 20
    National Collaborating Centre for Chronic Conditions.Osteoarthritis: national clinical guideline for care and management in adults. Appendix D.London:Royal College of Physicians;2008.
  • 21
    Maetzel A, Krahn M, Naglie G.The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis.Ottawa:Canadian Coordinating Office for Health Technology Assessment;2001.
  • 22
    Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir KR. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?Health Qual Life Outcomes 2008;6:51.
  • 23
    Statistics Canada. Canadian Community Health Survey: public use microdata file 2007/2008 (cycle 4.1).2009. URL: http://www5.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno=82M0013X&lang=eng.
  • 24
    Vestergaard P. Pain-relief medication and risk of fractures. Curr Drug Saf 2008;3:199203.
  • 25
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 2000;284:124755.
  • 26
    Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (the MEDAL study). Rheumatology (Oxford) 2009;48:42532.
  • 27
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:67584.
  • 28
    Wielage RC, Samsa GP, Klein TM, Happich M. A maximum likelihood simulation technique for estimating adverse event rates from published trials PRM145. In:International Society for Pharmacoeconomics and Outcomes Research 15th Annual European Congress.Berlin:ISPOR;2012.
  • 29
    Canadian Institute for Health Information.Proton pump inhibitor use in seniors: an analysis focusing on drug claims, 2001 to 2008.Canada:Canadian Institute for Health Information;2009.
  • 30
    Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331:13106.
  • 31
    Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
  • 32
    Washington State Department of Social & Health Services.Calculator: tapering plan for client with chronic, non-cancer pain.Lakewood (WA):Washington State Department of Social & Health Services;2009.
  • 33
    IMS-Brogan Inc.Delta PATM. Provincial formulary database, Quebec.Ottawa:IMS-Brogan;2011.
  • 34
    Ministry of Health and Long-Term Care. Ontario schedule of benefits for physician services.2010. URL: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html.
  • 35
    Ontario Case Costing Initiative. OCCI costing analysis tool.2010. URL: http://www.occp.com/.
  • 36
    Fraser Health. Hospice palliative care program symptom guidelines: nausea and vomiting.2006.
  • 37
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006;74:134754.
  • 38
    Maetzel A. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395401.
  • 39
    Work Loss Data Institute.Official disability guidelines. 15th ed.Encinitas (CA):WLDI;2010.
  • 40
    Kozhaya N.The retirement age in Quebec: a worrying situation.Montreal:Montreal Economic Institute;2007.
  • 41
    Gouvernement du Québec. Wages: commission des normes du travail du Québec.2010. URL: http://www.cnt.gouv.qc.ca/en/wages-pay-and-work/wages/index.html.
  • 42
    Tremblay DG, Najem E, Paquet R. Work-family balancing and working time: what measures are available to Canadian workers and what measures should employers develop?Glob J Bus Res 2007;1:97113.
  • 43
    Statistics Canada. Average hourly wages of employees by selected characteristics and profession, unadjusted data, by province (monthly) (Quebec).2011. URL: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr69f-eng.htm.
  • 44
    Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J Med Econ 2009;12:24658.
  • 45
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1278.
  • 46
    Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40:696703.
  • 47
    Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician 2008;11:S562.
  • 48
    O'Connor A, Noyes K, Holloway R. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 2008;26:104564.
  • 49
    Beard SM, Roskell N, Le TK, Zhao Y, Coleman A, Ang D, et al. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. J Med Econ 2011;14:46376.
  • 50
    Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M. The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective. Value Health 2013;16:33444.